All Title Author
Keywords Abstract

PLOS ONE  2014 

Clinical Oxidative Stress during Leprosy Multidrug Therapy: Impact of Dapsone Oxidation

DOI: 10.1371/journal.pone.0085712

Full-Text   Cite this paper   Add to My Lib


This study aims to assess the oxidative stress in leprosy patients under multidrug therapy (MDT; dapsone, clofazimine and rifampicin), evaluating the nitric oxide (NO) concentration, catalase (CAT) and superoxide dismutase (SOD) activities, glutathione (GSH) levels, total antioxidant capacity, lipid peroxidation, and methemoglobin formation. For this, we analyzed 23 leprosy patients and 20 healthy individuals from the Amazon region, Brazil, aged between 20 and 45 years. Blood sampling enabled the evaluation of leprosy patients prior to starting multidrug therapy (called MDT 0) and until the third month of multidrug therapy (MDT 3). With regard to dapsone (DDS) plasma levels, we showed that there was no statistical difference in drug plasma levels between multibacillary (0.518±0.029 μg/mL) and paucibacillary (0.662±0.123 μg/mL) patients. The methemoglobin levels and numbers of Heinz bodies were significantly enhanced after the third MDT-supervised dose, but this treatment did not significantly change the lipid peroxidation and NO levels in these leprosy patients. In addition, CAT activity was significantly reduced in MDT-treated leprosy patients, while GSH content was increased in these patients. However, SOD and Trolox equivalent antioxidant capacity levels were similar in patients with and without treatment. These data suggest that MDT can reduce the activity of some antioxidant enzyme and influence ROS accumulation, which may induce hematological changes, such as methemoglobinemia in patients with leprosy. We also explored some redox mechanisms associated with DDS and its main oxidative metabolite DDS-NHOH and we explored the possible binding of DDS to the active site of CYP2C19 with the aid of molecular modeling software.


[1]  World Health Organization (2012) Weekly epidemiological record. Global leprosy situation 34: 87–328, 87, 317-328 Available: htpp:// Accessed 28 April 2013.
[2]  Imbiriba ENB, Silva Neto AL, Souza WV, Pedrosa V, Cunha MG, et al. (2009) Desigualdad social, crecimiento urbano y hanseníasis en Manaus (Norte de Brasil): abordaje espacial. Rev Saúde Pública 43: 656–665.
[3]  Sanches LA, Pittner E, Sanches HF, Monteiro MC (2007) Detection of new cases of leprosy in the City of Prudentópolis, PR: the analysis from 1998 to 2005. Rev Soc Bras Med Trop 40: 541–545.
[4]  Sousa MW, Silva DC, Carneiro LR, Almino MLBF, Costa ALF (2012) Epidemiological profile of leprosy in the Brazilian state of Piauí between 2003 and 2008. An Bras Dermatol 87: 389–95.
[5]  Kwadijk S, Tora?o JS (2002) High-performance liquid chromatographic method with ultraviolet detection for the determination of dapsone and its hydroxylated metabolite in human plasma. Biomed Chromatogr 16: 203–208.
[6]  Zuidema J, Hilbers-Modderman ES, Merkus FW (1986) Clinical pharmacokinetics of dapsone. Clin Pharmacokinet 11: 299–315.
[7]  Coleman MD (1993) Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol 129: 507–13.
[8]  Mendes APS, Schalcher TR, Barros TG, Almeida ED, Maia CSF, et al. (2011) A Geometric and Electronic Study of Dapsone. J Comput Theor Nanosc 8: 1428–1431.
[9]  Coleman MD, Holden LJ (2004) The methaemoglobin forming and GSH depleting effects of dapsone and monoacetyl dapsone hydroxylamines in human diabetic and non-diabetic erythrocytes in vitro. Environmental toxicology and pharmacology 17: 55–59.
[10]  Veggi LM, Pretto L, Ochoa EJ, Catania VA, Luquita MG, et al. (2008) Dapsone induces oxidative stress and impairs antioxidant defenses in rat liver. Life Scie 83: 155–63.
[11]  Fleming CM, Branch RA, Wilkinson GR, Guengerich FP (1992) Human liver microsomal N-hydroxylation of dapsone by cytochrome P-4503A4. Molecular Pharmacology 41: 975–980.
[12]  Mitra AK, Thummel KE, Kalhorn TF, Kharasch ED, Unadkat JD, et al. (1995) Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. Clinical pharmacology and therapeutics 58: 556–566.
[13]  Hummel MA, Dickmann LJ, Rettie AE, Haining RL, Tracy TS (2004) Differential activation of CYP2C9 variants by dapsone Biochem. Pharmacol 67: 1831–1841.
[14]  Ganesan S, Sahu R, Walker LA, Tekwani BL (2010) Cytochrome P450-dependent toxicity of dapsone in human erythrocytes. Journal of Applied Toxicology 30: 271–275.
[15]  Rimiolli LF, Godoy MF (2001) Quantifica??o do estresse oxidativo no sangue de hansenianos sob efeito ou n?o de tratamento específico. Hansenol Int 26: 93–98.
[16]  Pinnell SR (2003) Cutaneous photodamage, oxidative stress, and topical antioxidant protection. J Am Acad Dermatol 48: 20–22.
[17]  Re R, Pellegrini N, Proteggente A, Pannala A, Yang M, et al. (1999) Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free radic biol med 26: 1231–1237.
[18]  Granger DL, Anstey NM, Miller WC, Weinberg JB (1999) Measuring nitric oxide production in human clinical studies. Methods Enzymol 301: 49–61.
[19]  Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82: 70–77.
[20]  Rom?o PR, Tovar J, Fonseca SG, Moraes RH, Cruz AK, et al. (2006) Glutathione and the redox control system trypanothione/trypanothione reductase are involved in the protection of Leishmania spp. against nitrosothiol-induced cytotoxicity. Braz j med biol res 39: 355–363.
[21]  McCord JM, Fridovich I (1969) Superoxide dismutase an enzymic function for erythrocuprein (hemocuprein). J Biol Chem 244: 6049–6055.
[22]  Beutler E (1975) The preparation of red cells for assay. In Bleuter, E. (ed.) Red Cell Metabolism: A manual of biochemical methods. New York: Grune Straton p. 8–18.
[23]  Thomsen R, Christensen MH (2006) MolDock:?A New Technique for High-Accuracy Molecular Docking,. J Med Chem 49: 3315–3321.
[24]  B?hm HJ, Schneider G (2008) (eds) Frontmatter, In: Virtual Screening for Bioactive Molecules, Wiley-VCH Verlag GmbH, Weinheim, Germany.
[25]  Reynald RL, Sansen S, Stout CD, Johnson EF (2012) Structural Characterization of Human Cytochrome P450 2C19: active site differences between P450s 2C8, 2C9, AND 2C19.,. J Biol Chem 287: 44581–44591.
[26]  Szabo A, Ostlund NS (1989) Modern Quantum Chemistry: Introduction to Advanced Electronic Structure Theory, McGraw-Hill: New York.
[27]  Zoete V, Grosdidier A, Michielin O (2009) Docking, virtual high throughput screening and in silico fragment-based drug design. J Cel Mol Med 13: 238–248.
[28]  Vieira JL, Riveira JG, Martins ADEN, Silva JP, Salgado CG (2010) Methemoglobinemia and dapsone levels in patients with leprosy. Braz j infect Dis 14: 319–32.
[29]  Carrazza MZN, Carrazza FR, Oga S (2000) Clinical and laboratory parameters in dapsone acute intoxication. Rev Saúde Pública 34: 396–401.
[30]  Price D (1994) Methemoglobinemia. In: Goldfrank LR, Flomenbaum NA, Lewin NA, Weisman RS, Howland, MA Hoffman RS, editors. Goldfrank's toxicologic emergencies Norwalk: Appleton & Lange. pp. 1169–1178.
[31]  Barnes J, Barnes EJ (1951) Liver damage during treatment with DDS. Lepr Rev 12: 54–56.
[32]  Ellard GA (1966) Absorption, metabolism and excretion of di(p-aminophenyl) sulphone (dapsone) and di(p-aminophenyl) sulphoxide in man. Br j pharmacol chemother 26: 212–217.
[33]  Tingle MD, Mahmud R, Maggs JL, Pirmohamed M, Park BK (1997) Comparison of the Metabolism and Toxicity of Dapsone in Rat, Mouse and Man. J pharmacol exp ther 283: 817–823.
[34]  Grace M (2011) An unusual case of dapsone syndrome. Indian Dermatol Online J 2: 88–90.
[35]  Borges RS, Vale JKL, Schalcher TR, Almeida ED, Maia CSF (2013) A Theoretical Study of the Dapsone Derivatives on Methemoglobin. Journal of Computational and Theoretical Nanoscience 10: 1–5.
[36]  Trindade MAB, Careta MF (2008) Acute methemoglobinemia induced by dapsone. Hansen Int 33: 31–34.
[37]  Coleman MD, Coleman NA (1996) Drug-Induced Methaemoglobinaemia. Drug Safet 14: 394–405.
[38]  White JC, Beaven GH (1959) Fetal haemoglobin. Br Med Bull 15: 33–39.
[39]  Queiroz RH, Melchior Júnior E, de Souza AM, Gouveia E, Barbosa JC (1997) Haematological and biochemical alterations in leprosy patients already treated with dapsone and MDT. Pharmaceutica Acta Helvetiae 72: 209–213.
[40]  Dalpino D, Diltor LAM, Opromolla VA (1998) Atividade da NADH-redutase de metemoglobina em hemolisado e membranas eritrocitárias de pacientes hansenianos sob tratamento sulf?nico. Hansen Int 23: 14–26.
[41]  Smith RS, Alexander S (1959) Heinz-body Anaemia due to Dapsone. Br Med J 7: 625–627.
[42]  Mahmud R, Tingle MD, Maggs JL, Cronin MTD, Dearden JC, et al. (1997) Structural basis for the haemotoxicity of dapsone: the importance of the sulphonyl group. Toxicology 117: 1–11.
[43]  Schalcher TR, Vieira JLF, Salgado CG, Borges RS, Monteiro MC (2013) Antioxidant factors, nitric oxide levels, and cell damage in leprosy patients. Rev Soc Bras Med Trop 46: 645–649.
[44]  Khanolkar-Young S, Snowdon D, Lockwood DN (1998) Immunocytochemical localization of inducible nitric oxide synthase and transforming growth factorbeta (TGF-beta) in leprosy lesions. Clin Exp Immunol 113: 438–442.
[45]  Sch?n T, Hernandez-Pando RH, Negesse Y, Leekassa R, Sundqvist T (2001) Expression of inducible nitric oxide synthase and nitrotyrosine in borderline leprosy lesions. Br J Dermatol 145: 809–15.
[46]  Bickers DR, Athar M (2006) Oxidative Stress in the Pathogenesis of Skin Disease. Journal of Investigative Dermatology 126: 2565–2575.
[47]  Moraes NV, Mello MH, Souza AM, Sampaio SV, Queiroz RHC (2008) Potentiation of dapsone induced methemoglobinemia by N-acetylcysteine in rats. Rev Bras Cienc Farm 44: 97–104.
[48]  Patten AR, Brocardo PS, Christie BR (2013) Omega-3 supplementation can restore glutathione levels and prevent oxidative damage caused by prenatal ethanol exposure. J Nutr Biochem 24): 760–769.
[49]  Jian W, Arora JS, Oe T, Shuvaev VV, Blair IA (2005) Induction of endothelial cell apoptosis by lipid hydroperoxide-derived bifunctional electrophiles. Free Radic Biol Med 39: 1162–76.
[50]  Switala J, Loewen PC (2002) Diversity of properties among catalases. Arch biochem biophys 401: 145–154.
[51]  Prasad CVB, Kodliwadmath MV, Kodliwadmath GB (2007) Erythrocyte superoxide dismutase, catalase activities and hydrogen peroxide induced lipid peroxidation in leprosy. Lepr Rev 78: 391–397.
[52]  Reimer DL, Bailley J, Singh SM (1994) Complete cDNA and 5′ genomic sequences and multilevel regulation of the mouse catalase gene. Genomics 21: 325–336.
[53]  Banerjee P, Bhattacharyya SS, Patha S, Boujedaini N, Belon P, et al. (2011) Evidences of protective potentials of microdoses of ultra-high diluted arsenic trioxide in mice receiving repeated injections of arsenic trioxide. Evid Based Complement Alternat Med 2011: 391752 doi: 10.1093/ecam/nen090.
[54]  Osadolor HB, Ihongbe JC (2008) Effect of leprosy on non-enzymatic antioxidants (vitamin c, vitamin e and uric acid) in (edo state) nigerian leprosy patients. Continental J. Biomedical Sciences 2: 1–5.
[55]  Van Den Berg R, Haenen GRMM, Van Den Berg H (1999) Applicability of an improved Trolox equivalent antioxidant capacity (TEAC) assay for evaluation of antioxidant capacity measurements of mixtures. Food Chemistry 66: 511–517.
[56]  Ghiselli A, Serafini M, Natella F, Scaccini C (2000) Total antioxidant capacity as a tool to assess redox status: critical view and experimental data. Free Radic Biol Med 29: 1106–14.
[57]  Gill HJ, Tingle MD, Park BK (1995) N-hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity. British Journal of ClinicalPharmacology 40: 531–539.
[58]  Wright JD, Helsby NA, Ward SA (1995) The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides. British Journal of Clinical Pharmacology 39: 441–444.


comments powered by Disqus